Fatemeh Nejatbakhsh
Research Subjects
Fatemeh Nejatbakhsh has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Fatemeh Shabani
Department of Midwifery, School of Medicine, Arak University of Medical Sciences, Arak, Iran
3 shared publications - Malihe Tabarrai
Department of Persian Medicine, School of Persian Medicine, Tehran University of Medical Sciences, Tehran, Iran
3 shared publications - Mohammad Ali Zareian
Department of Traditional Medicine, School of Persian Medicine, Tehran University of Medical Sciences, Tehran, Iran
3 shared publications - Katayon Vakilian
Department of Midwifery, School of Medicine, Arak University of Medical Sciences, Arak, Iran
2 shared publications - Mahbubeh Bozorgi
Department of Traditional Persian Medicine, Faculty of Persian Medicine, Shahed University, Tehran, Iran
2 shared publications - Roja Rahimi
Department of Traditional Pharmacy School of Persian Medicine Tehran University of Medical Sciences Tehran Iran
2 shared publications
Latest Publications
- 26 October 2026
- Published by Wiley in Musculoskeletal Care
- Vol. 24 (4)
Efficacy and Safety of Ushaq Capsule as Adjunctive Therapy in Patients With Lumbar Radiculopathy: A Double‐Blind, Randomized, Placebo‐Controlled Clinical Trial at Imam Khomeini Hospital, Tehran, Iran
Background: Sciatica and lumbar radicular pain are prevalent symptoms affecting a large proportion of people worldwide. Many patients seek complementary and alternative medicine for pain relief. This study aimed to evaluate the efficacy and safety of Ushaq capsule, a herbal formulation from Traditional Persian Medicine, on pain intensity and disability in patients with lumbar radiculopathy. Methods: This randomized, double‐blind, placebo‐controlled clinical trial included 68 patients randomly assigned to intervention or placebo groups. All participants were allowed to use diclofenac 50 mg (up to three tablets daily) as rescue medication for breakthrough pain. Participants in the intervention group received 3 Ushaq capsules daily for 6 weeks, while the placebo group received identical microcrystalline cellulose capsules. Pain intensity and disability were assessed using the Visual Analogue Scale (VAS) and Roland Morris Disability Questionnaire (RMDQ). The primary endpoint was the change in VAS score from baseline to week 6. Safety was evaluated through clinical adverse event monitoring and laboratory tests. Results: No significant baseline differences were observed between the groups ( p > 0.05). The mean VAS score was significantly lower in the Ushaq group from the second week onward ( p = 0.019) and remained significant until the end of the study ( p = 0.003). The RMDQ score decreased significantly in both groups, but the reduction in the Ushaq group was not significantly greater than that in the placebo group ( p = 0.218). No serious adverse events were reported; only mild, transient gastrointestinal discomfort occurred ( Ushaq : 6.5%, placebo: 4.3%). Conclusions: Ushaq capsules as adjunctive therapy with diclofenac as rescue medication showed greater pain reduction compared to placebo with a favourable safety profile. Larger, longer‐term trials with active comparators are needed to confirm these preliminary findings. Trail Registration: The research was registered with the Iranian Registry of Clinical Trials (IRCT) and received registration number IRCT20200418047124N1
- 26 October 2026
- Published by Wiley in Musculoskeletal Care
- Vol. 24 (4)
Efficacy and Safety of Ushaq Capsule as Adjunctive Therapy in Patients With Lumbar Radiculopathy: A Double‐Blind, Randomized, Placebo‐Controlled Clinical Trial at Imam Khomeini Hospital, Tehran, Iran
Background: Sciatica and lumbar radicular pain are prevalent symptoms affecting a large proportion of people worldwide. Many patients seek complementary and alternative medicine for pain relief. This study aimed to evaluate the efficacy and safety of Ushaq capsule, a herbal formulation from Traditional Persian Medicine, on pain intensity and disability in patients with lumbar radiculopathy. Methods: This randomized, double‐blind, placebo‐controlled clinical trial included 68 patients randomly assigned to intervention or placebo groups. All participants were allowed to use diclofenac 50 mg (up to three tablets daily) as rescue medication for breakthrough pain. Participants in the intervention group received 3 Ushaq capsules daily for 6 weeks, while the placebo group received identical microcrystalline cellulose capsules. Pain intensity and disability were assessed using the Visual Analogue Scale (VAS) and Roland Morris Disability Questionnaire (RMDQ). The primary endpoint was the change in VAS score from baseline to week 6. Safety was evaluated through clinical adverse event monitoring and laboratory tests. Results: No significant baseline differences were observed between the groups ( p > 0.05). The mean VAS score was significantly lower in the Ushaq group from the second week onward ( p = 0.019) and remained significant until the end of the study ( p = 0.003). The RMDQ score decreased significantly in both groups, but the reduction in the Ushaq group was not significantly greater than that in the placebo group ( p = 0.218). No serious adverse events were reported; only mild, transient gastrointestinal discomfort occurred ( Ushaq : 6.5%, placebo: 4.3%). Conclusions: Ushaq capsules as adjunctive therapy with diclofenac as rescue medication showed greater pain reduction compared to placebo with a favourable safety profile. Larger, longer‐term trials with active comparators are needed to confirm these preliminary findings. Trail Registration: The research was registered with the Iranian Registry of Clinical Trials (IRCT) and received registration number IRCT20200418047124N1
- Open Access
- 5 January 2023
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2023 (1) , 5069471
Dietary Modifications in Critically‐Ill Patients: A Comparison of Persian Medicine and Conventional Medicine Perspectives
In Persian Medicine (PM) literature, a crisis is the culmination of the body’s response to illness, which necessitates fundamental dietary modification to improve prognosis. In this narrative review, authentic PM textbooks as well as articles on diets for critically‐ill patients (CIPs) obtained from PubMed and Google Scholar databases, were reviewed, and after gathering data, they were classified, coded, analyzed, and compared. In the acute phase, both PM and conventional medicine agree on relative food restriction, but PM lays a special focus on the use of meat in cases of weakness. There are both similarities and differences between PM and conventional medicine regarding nutritional recommendations in critical illness. For example, recommendations for food restriction and protein intake are similar in both schools, but recommendations for carbohydrate intake are different. The variables addressed and emphasized in PM require further evaluation in clinical trials.
- 5 January 2023
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2023 (1) , 5069471
Open AccessDietary Modifications in Critically‐Ill Patients: A Comparison of Persian Medicine and Conventional Medicine Perspectives
In Persian Medicine (PM) literature, a crisis is the culmination of the body’s response to illness, which necessitates fundamental dietary modification to improve prognosis. In this narrative review, authentic PM textbooks as well as articles on diets for critically‐ill patients (CIPs) obtained from PubMed and Google Scholar databases, were reviewed, and after gathering data, they were classified, coded, analyzed, and compared. In the acute phase, both PM and conventional medicine agree on relative food restriction, but PM lays a special focus on the use of meat in cases of weakness. There are both similarities and differences between PM and conventional medicine regarding nutritional recommendations in critical illness. For example, recommendations for food restriction and protein intake are similar in both schools, but recommendations for carbohydrate intake are different. The variables addressed and emphasized in PM require further evaluation in clinical trials.
- Open Access
- 1 January 2023
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2023 (1) , 5355993
Effectiveness of Persian Golnar on Excessive Menstrual Bleeding in Women with Abnormal Uterine Bleeding, Compared to Tranexamic Acid: A Triple‐Blind, Randomized Equivalence Trial
Introduction. Abnormal uterine bleeding (AUB) is a major healthcare problem in females of reproductive age and impacts women’s health and quality of life (QoL). This study aimed to test the equivalence of Persian Golnar (PG) and tranexamic acid (TA) for the treatment of excessive menstrual bleeding. Method. A triple‐blind randomized equivalence trial with parallel design and block randomization technique was performed. A total of 80 patients with AUB were randomly allocated to receive either PG or TA for three consecutive menstrual cycles. Blood loss was measured by the Pictorial Blood Loss Assessment Chart (PBAC). Hematological evaluations were done before the intervention and after treatment. QoL and premenstrual dysphoric disorder (PMDD) as secondary outcomes were assessed using the menorrhagia questionnaire (MQ) and Premenstrual Symptoms Screening Tool (PSST). Statistical analysis was performed using an independent t‐test, paired t‐test, χ2 test, Mann–Whitney test, and Wilcoxon signed‐rank test. Results. Seventy‐six women completed the 12‐week follow‐up. Both PG and TA groups experienced a significant reduction in blood loss. Furthermore, the serum level of hemoglobin in the PG group enhanced significantly (P < 0.001). QoL and PMDD scores were significantly improved in both groups (P< 0.001). Conclusion. The findings of the current trial supposed that the Golnar product is as effective as tranexamic acid in controlling bleeding and enhancing the quality of life and premenstrual symptoms.
- 1 January 2023
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2023 (1) , 5355993
Open AccessEffectiveness of Persian Golnar on Excessive Menstrual Bleeding in Women with Abnormal Uterine Bleeding, Compared to Tranexamic Acid: A Triple‐Blind, Randomized Equivalence Trial
Introduction. Abnormal uterine bleeding (AUB) is a major healthcare problem in females of reproductive age and impacts women’s health and quality of life (QoL). This study aimed to test the equivalence of Persian Golnar (PG) and tranexamic acid (TA) for the treatment of excessive menstrual bleeding. Method. A triple‐blind randomized equivalence trial with parallel design and block randomization technique was performed. A total of 80 patients with AUB were randomly allocated to receive either PG or TA for three consecutive menstrual cycles. Blood loss was measured by the Pictorial Blood Loss Assessment Chart (PBAC). Hematological evaluations were done before the intervention and after treatment. QoL and premenstrual dysphoric disorder (PMDD) as secondary outcomes were assessed using the menorrhagia questionnaire (MQ) and Premenstrual Symptoms Screening Tool (PSST). Statistical analysis was performed using an independent t‐test, paired t‐test, χ2 test, Mann–Whitney test, and Wilcoxon signed‐rank test. Results. Seventy‐six women completed the 12‐week follow‐up. Both PG and TA groups experienced a significant reduction in blood loss. Furthermore, the serum level of hemoglobin in the PG group enhanced significantly (P < 0.001). QoL and PMDD scores were significantly improved in both groups (P< 0.001). Conclusion. The findings of the current trial supposed that the Golnar product is as effective as tranexamic acid in controlling bleeding and enhancing the quality of life and premenstrual symptoms.
- Open Access
- 23 August 2022
- Published by Bentham Science Publishers Ltd. in The Open Public Health Journal
- Vol. 15 (1)
Comparing the Effect of Chamomile and Mefenamic Acid on Primary Dysmenorrhea Symptoms and Menstrual Bleeding: A Randomized Clinical Trial
Background: Dysmenorrhea in young women reduces their quality of life. Objectives: This research reviewed the impact of chamomile sachet and mefenamic acid on primary dysmenorrhea, its relevant symptoms as well as bleeding. Methods: Two hundred female students afflicted with primary dysmenorrhea from Arak universities were randomly assigned to two groups and participated in this randomized clinical trial. The first group (A) received mefenamic acid (250 mg) and the second group (B) received chamomile (5000 mg) three times a day in two consecutive cycles from two days before up to the first three days after menstruation. Intensity of pain, related symptoms and bleeding were evaluated by visual analog scale, Andersch-Milsom Verbal Scale and Higham chart, respectively. Data analysis was performed by SPSS 21. Results: Severe pain lasting two months after intervention was observed in 6 subjects (6.3%) of group (B) as well as 6 participants (6.3%) in group (A) (p=0.351, p=0.332). Two months after treatment, mean severity of related symptoms was 4.93±3.54 in group (B) and 5.62±3.54 in group (A), which shows further reduction of pain in group (B) that was not significant (p=0.278). Two months later, mean of bleeding was 88.71±66.4 and 70.54 ±53. 34 in group (B) and (A), respectively. Thus, the decrease of pain in the two groups was not significant (p=0.567). Conclusion: It appears that chamomile sachet can decrease the severity of pain and bleeding, which is similar to the effect of mefenamic acid and even further alleviates the symptoms of dysmenorrhea. (IRCT code no. 20161008250B1N5).
- 23 August 2022
- Published by Bentham Science Publishers Ltd. in The Open Public Health Journal
- Vol. 15 (1)
Open AccessComparing the Effect of Chamomile and Mefenamic Acid on Primary Dysmenorrhea Symptoms and Menstrual Bleeding: A Randomized Clinical Trial
Background: Dysmenorrhea in young women reduces their quality of life. Objectives: This research reviewed the impact of chamomile sachet and mefenamic acid on primary dysmenorrhea, its relevant symptoms as well as bleeding. Methods: Two hundred female students afflicted with primary dysmenorrhea from Arak universities were randomly assigned to two groups and participated in this randomized clinical trial. The first group (A) received mefenamic acid (250 mg) and the second group (B) received chamomile (5000 mg) three times a day in two consecutive cycles from two days before up to the first three days after menstruation. Intensity of pain, related symptoms and bleeding were evaluated by visual analog scale, Andersch-Milsom Verbal Scale and Higham chart, respectively. Data analysis was performed by SPSS 21. Results: Severe pain lasting two months after intervention was observed in 6 subjects (6.3%) of group (B) as well as 6 participants (6.3%) in group (A) (p=0.351, p=0.332). Two months after treatment, mean severity of related symptoms was 4.93±3.54 in group (B) and 5.62±3.54 in group (A), which shows further reduction of pain in group (B) that was not significant (p=0.278). Two months later, mean of bleeding was 88.71±66.4 and 70.54 ±53. 34 in group (B) and (A), respectively. Thus, the decrease of pain in the two groups was not significant (p=0.567). Conclusion: It appears that chamomile sachet can decrease the severity of pain and bleeding, which is similar to the effect of mefenamic acid and even further alleviates the symptoms of dysmenorrhea. (IRCT code no. 20161008250B1N5).
- Open Access
- 30 May 2022
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2022, 1-8
An Add-On Treatment for Moderate COPD with Squill-Oxymel (a Traditional Formulation from Drimia maritima (L.) Stearn): A Pilot Randomized Triple-Blinded Placebo-Controlled Clinical Trial
Background. In traditional Persian medicine, Drimia maritima, with the popular name Squill, has been used to alleviate phlegm dyspnea. Squill has also been shown to have anti-inflammatory and anticholinergic properties. The goal of this research was to see how effective and safe Squill-Oxymel was in treating COPD patients. Method. Forty-two COPD patients were examined for eight weeks in two groups. Patients underwent a 6-minute walk test to assess the treatment’s effectiveness at the beginning and conclusion of the intervention. We utilized St. George’s Respiratory Questionnaire (SGRQ) to evaluate the subjective symptoms of patients in order to measure their quality of life. Results. Patients who received Squill-Oxymel showed a statistically significant increase in 6MWT distance ( ). The mean O2 saturation at the end of the 6MWT before the intervention was significantly greater in the placebo group. ( ). In terms of questionnaire variables, there was a significant difference between placebo and Squill-Oxymel groups in the mean presymptom score ( ) and the mean post-symptom score ( ). Conclusions. The findings of this research provide preliminary evidence for the effectiveness and safety of Squill-Oxymel as an add-on therapy in individuals with mild COPD.
- 30 May 2022
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2022, 1-8
Open AccessAn Add-On Treatment for Moderate COPD with Squill-Oxymel (a Traditional Formulation from Drimia maritima (L.) Stearn): A Pilot Randomized Triple-Blinded Placebo-Controlled Clinical Trial
Background. In traditional Persian medicine, Drimia maritima, with the popular name Squill, has been used to alleviate phlegm dyspnea. Squill has also been shown to have anti-inflammatory and anticholinergic properties. The goal of this research was to see how effective and safe Squill-Oxymel was in treating COPD patients. Method. Forty-two COPD patients were examined for eight weeks in two groups. Patients underwent a 6-minute walk test to assess the treatment’s effectiveness at the beginning and conclusion of the intervention. We utilized St. George’s Respiratory Questionnaire (SGRQ) to evaluate the subjective symptoms of patients in order to measure their quality of life. Results. Patients who received Squill-Oxymel showed a statistically significant increase in 6MWT distance ( ). The mean O2 saturation at the end of the 6MWT before the intervention was significantly greater in the placebo group. ( ). In terms of questionnaire variables, there was a significant difference between placebo and Squill-Oxymel groups in the mean presymptom score ( ) and the mean post-symptom score ( ). Conclusions. The findings of this research provide preliminary evidence for the effectiveness and safety of Squill-Oxymel as an add-on therapy in individuals with mild COPD.
- 9 September 2020
- Published by Bentham Science Publishers Ltd. in Current Women s Health Reviews
- Vol. 16 (4) , 348-358
The Effect of Ginger-chamomile Sachet with Honey on Primary Dysmenorrhea and Associated Symptoms: A Randomized, Double-Blind, Controlled Trial
Background: Dysmenorrhea is one of the most frequent pelvic pains among young women, impairing their quality of life.Objective: This research aims to investigate the effect of ginger-chamomile herbs with honey in reducing dysmenorrhea pain, associated symptoms, and the extent of bleeding.Methods: In this randomized clinical trial (IRCT No.: 2016100825031N5), 200 female students with primary dysmenorrhea, from Arak universities, were included and randomly divided into two groups. All the students were evaluated for one cycle without intervention, then group (A) received mefenamic acid (250 mg) and group (B) received ginger (1000 mg), chamomile (5000 mg), and one teaspoonful of honey for two days before and for the first three days of menstruation, three times a day, in two consecutive cycles. Pain severity, associated symptoms of dysmenorrhea, and bleeding were assessed using a visual analogue scale, Andersch-Milsom Verbal Scale, and Higham chart. Data were analyzed by descriptive and inferential statistical tests through SPSS21.Results: The pain intensity in group B diminished significantly after the intervention in comparison to group A (p <0.05). The mean severity of dysmenorrhea accompanying symptoms decreased significantly in group B compared to group A (P=0.009). However, the mean quantity of bleeding significantly decreased in group A (P = 0.004), with no increase in the extent of bleeding in group B.Conclusion: The present study indicated that the combination of the ginger-chamomile sachet with honey has the same effect as nonsteroidal anti-inflammatory drugs for pain mitigation, and the associated symptoms reduced better than mefenamic acid.
- 9 September 2020
- Published by Bentham Science Publishers Ltd. in Current Women s Health Reviews
- Vol. 16 (4) , 348-358
The Effect of Ginger-chamomile Sachet with Honey on Primary Dysmenorrhea and Associated Symptoms: A Randomized, Double-Blind, Controlled Trial
Background: Dysmenorrhea is one of the most frequent pelvic pains among young women, impairing their quality of life.Objective: This research aims to investigate the effect of ginger-chamomile herbs with honey in reducing dysmenorrhea pain, associated symptoms, and the extent of bleeding.Methods: In this randomized clinical trial (IRCT No.: 2016100825031N5), 200 female students with primary dysmenorrhea, from Arak universities, were included and randomly divided into two groups. All the students were evaluated for one cycle without intervention, then group (A) received mefenamic acid (250 mg) and group (B) received ginger (1000 mg), chamomile (5000 mg), and one teaspoonful of honey for two days before and for the first three days of menstruation, three times a day, in two consecutive cycles. Pain severity, associated symptoms of dysmenorrhea, and bleeding were assessed using a visual analogue scale, Andersch-Milsom Verbal Scale, and Higham chart. Data were analyzed by descriptive and inferential statistical tests through SPSS21.Results: The pain intensity in group B diminished significantly after the intervention in comparison to group A (p <0.05). The mean severity of dysmenorrhea accompanying symptoms decreased significantly in group B compared to group A (P=0.009). However, the mean quantity of bleeding significantly decreased in group A (P = 0.004), with no increase in the extent of bleeding in group B.Conclusion: The present study indicated that the combination of the ginger-chamomile sachet with honey has the same effect as nonsteroidal anti-inflammatory drugs for pain mitigation, and the associated symptoms reduced better than mefenamic acid.
- Open Access
- 22 July 2020
- Published by Springer Nature in Research Square
Comparison of the effect of Chamomile and Mefenamic Acid on primary dysmenorrhea, associated symptoms and menstrual bleeding – A randomized clinical trial study
Background Dysmenorrhea is one of the most common pelvic pains in women, impairing their quality of life.This study investigated the effects of chamomile sachet and mefenamic acid on primary dysmenorrhea, associated symptoms and bleeding. Methods In this randomized clinical trial, 200 female students with primary dysmenorrhea from Arak universities were randomly assigned to two groups. The group (A) received mefenamic acid (250 mg) and group (B) received chamomile (5000 mg) plus one teaspoonful of honey )as a flavoring( for two days before up to the first three days of menstruation, three times a day in two consecutive cycles. Pain severity, associated symptoms and bleeding were assessed using visual analog scale, Andersch-Milsom Verbal Scale and Higham chart, respectively. Data were analyzed by descriptive and inferential statistical tests by SPSS 21. Results Severe pain during two months after intervention was in 6 (6.3%) of group (B) and 6 (6.3%) in group (A) (p = 0.351, p = 0.332). Mean severity of associated symptoms two months after the treatment was( 4.93 ± 3.54) in group (B) and (5.62 ± 3.54 ) in group (A), indicating further reduction in group (B) but not significant (p = 0.278). Mean of bleeding was (88.71 ± 66.4 vs. 70.54 ± 53. 34) in group (B) and (A) respectively, in two months later. therefore decrease in the two groups but was not significant between groups(p = 0.567). Conclusions It seems chamomile sachet can reduce the severity of pain and bleeding similar to mefenamic acid and even further mitigate the symptoms associated with dysmenorrhea. Trial registration: This study was performed with the proposal approval code of 2611, ethics code of (ARAKMU.REC.1395.164) at Arak University of medical sciences and code of IRCT 2016100825031N5 on 2016.11.08.
- 22 July 2020
- Published by Springer Nature in Research Square
Open AccessComparison of the effect of Chamomile and Mefenamic Acid on primary dysmenorrhea, associated symptoms and menstrual bleeding – A randomized clinical trial study
Background Dysmenorrhea is one of the most common pelvic pains in women, impairing their quality of life.This study investigated the effects of chamomile sachet and mefenamic acid on primary dysmenorrhea, associated symptoms and bleeding. Methods In this randomized clinical trial, 200 female students with primary dysmenorrhea from Arak universities were randomly assigned to two groups. The group (A) received mefenamic acid (250 mg) and group (B) received chamomile (5000 mg) plus one teaspoonful of honey )as a flavoring( for two days before up to the first three days of menstruation, three times a day in two consecutive cycles. Pain severity, associated symptoms and bleeding were assessed using visual analog scale, Andersch-Milsom Verbal Scale and Higham chart, respectively. Data were analyzed by descriptive and inferential statistical tests by SPSS 21. Results Severe pain during two months after intervention was in 6 (6.3%) of group (B) and 6 (6.3%) in group (A) (p = 0.351, p = 0.332). Mean severity of associated symptoms two months after the treatment was( 4.93 ± 3.54) in group (B) and (5.62 ± 3.54 ) in group (A), indicating further reduction in group (B) but not significant (p = 0.278). Mean of bleeding was (88.71 ± 66.4 vs. 70.54 ± 53. 34) in group (B) and (A) respectively, in two months later. therefore decrease in the two groups but was not significant between groups(p = 0.567). Conclusions It seems chamomile sachet can reduce the severity of pain and bleeding similar to mefenamic acid and even further mitigate the symptoms associated with dysmenorrhea. Trial registration: This study was performed with the proposal approval code of 2611, ethics code of (ARAKMU.REC.1395.164) at Arak University of medical sciences and code of IRCT 2016100825031N5 on 2016.11.08.
- Open Access
- 1 January 2020
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2020 (1) , 6667078
The Effects of Aromatherapy on Premenstrual Syndrome Symptoms: A Systematic Review and Meta‐Analysis of Randomized Clinical Trials
ObjectivesPremenstrual syndrome (PMS) is a common disturbance among women of childbearing age. Aromatherapy is a commonly used form of complementary and alternative medicine (CAM) to treat PMS. The purpose of this study is to quantify and summarize the effects of aromatherapy on premenstrual syndrome symptoms. Methods. PubMed, Scopus, and Cochrane Library databases were searched through relevant search terms until October 2020. The effect sizes were pooled as weighted mean difference (WMD) and 95% confidence interval (CI) using the random effect model. Egger tests and visual inspection of the funnel plot were performed to identify the existence of publication bias. The I‐squared (I2) test was applied to measure heterogeneity. Results. Eight studies (n = 8) were included in this analysis. The quantitative synthesis of evidence found that aromatherapy decreases PMS scores (WMD –13.83; 95% CI (−22.04, −5.63), I2 = 94.5%), total psychological symptoms of PMS (WMD –3.51; 95% CI (−4.84, −2.18), I2 = 82.6%), anxiety of PMS (WMD–1.78; 95% CI (−3.17, −0.38), I2 = 94.2%), depression of PMS (WMD–2.0; 95% CI (−3.65, −0.34), I2 = 93.7%), and fatigue of PMS (WMD – 1.44; 95% CI (−2.44, −0.44), I2 = 89.7%) compared to the control group. Conclusion. Aromatherapy is an effective tool for the relief of PMS symptoms. Additional randomized controlled clinical trials with different durations and essential oils should be conducted to confirm our findings.
- 1 January 2020
- Published by Wiley in Evidence-Based Complementary and Alternative Medicine
- Vol. 2020 (1) , 6667078
Open AccessThe Effects of Aromatherapy on Premenstrual Syndrome Symptoms: A Systematic Review and Meta‐Analysis of Randomized Clinical Trials
ObjectivesPremenstrual syndrome (PMS) is a common disturbance among women of childbearing age. Aromatherapy is a commonly used form of complementary and alternative medicine (CAM) to treat PMS. The purpose of this study is to quantify and summarize the effects of aromatherapy on premenstrual syndrome symptoms. Methods. PubMed, Scopus, and Cochrane Library databases were searched through relevant search terms until October 2020. The effect sizes were pooled as weighted mean difference (WMD) and 95% confidence interval (CI) using the random effect model. Egger tests and visual inspection of the funnel plot were performed to identify the existence of publication bias. The I‐squared (I2) test was applied to measure heterogeneity. Results. Eight studies (n = 8) were included in this analysis. The quantitative synthesis of evidence found that aromatherapy decreases PMS scores (WMD –13.83; 95% CI (−22.04, −5.63), I2 = 94.5%), total psychological symptoms of PMS (WMD –3.51; 95% CI (−4.84, −2.18), I2 = 82.6%), anxiety of PMS (WMD–1.78; 95% CI (−3.17, −0.38), I2 = 94.2%), depression of PMS (WMD–2.0; 95% CI (−3.65, −0.34), I2 = 93.7%), and fatigue of PMS (WMD – 1.44; 95% CI (−2.44, −0.44), I2 = 89.7%) compared to the control group. Conclusion. Aromatherapy is an effective tool for the relief of PMS symptoms. Additional randomized controlled clinical trials with different durations and essential oils should be conducted to confirm our findings.
- Open Access
- 30 December 2019
- Published by Negah Scientific Publisher in Journal of Pediatrics Review
- Vol. 8 (1) , 15-22
Nocturnal Enuresis in Children and Its Herbal Remedies in Medieval Persia: A Narrative Review
Context: Nocturnal Enuresis (NE) refers to intermittent involuntary voiding during sleep in a child aged five years or more without any other urinary tract symptoms. Although pharmacological interventions are useful, the NE of most children relapses after the medication is discontinued. Persian Medicine (PM), as an complementary and alternative medicine, offers ...
- 30 December 2019
- Published by Negah Scientific Publisher in Journal of Pediatrics Review
- Vol. 8 (1) , 15-22
Open AccessNocturnal Enuresis in Children and Its Herbal Remedies in Medieval Persia: A Narrative Review
Context: Nocturnal Enuresis (NE) refers to intermittent involuntary voiding during sleep in a child aged five years or more without any other urinary tract symptoms. Although pharmacological interventions are useful, the NE of most children relapses after the medication is discontinued. Persian Medicine (PM), as an complementary and alternative medicine, offers ...
- 1 August 2019
- Published by Elsevier in Complementary Therapies in Clinical Practice
- Vol. 36, 170-175
Effect of sweet almond syrup versus methylphenidate in children with ADHD: A randomized triple-blind clinical trial
- 1 August 2019
- Published by Elsevier in Complementary Therapies in Clinical Practice
- Vol. 36, 170-175
Effect of sweet almond syrup versus methylphenidate in children with ADHD: A randomized triple-blind clinical trial